<DOC>
	<DOCNO>NCT01457989</DOCNO>
	<brief_summary>The objective meta-analysis provide data long-term safety efficacy follow recent positive Committee Medicinal Products Human Use ( CHMP ) opinion retigabine use pool data ongoing open-label extension ( OLE ) Studies VRX-RET-E22-303 VRX-RET-E22-304 .</brief_summary>
	<brief_title>Meta-Analysis Plan Pooled Data Studies VRX-RET-E22-303 VRX-RET-E22-304</brief_title>
	<detailed_description>Data October 2009 data-cut ongoing Studies VRX-RET-E22-303 ( Study 303 ) VRX-RET-E22-304 ( Study 304 ) pool , summarize , publish goal provide updated long-term safety efficacy information subject prescribers follow recent positive CHMP opinion retigabine adjunctive use patient partial seizure . Studies 303 304 open-label extension two Phase 3 study ( VRX-RET-E22-301 VRX-RET-E22-302 ) , respectively . Studies 301 302 randomize , double-blind , placebo-controlled , parallel-group , multicenter study 600 mg 900 mg per day ( Study 302 ) 1200 mg per day ( Study 301 ) . All subject wish enter OLE study , opinion investigator , expect benefit participation OLEs , enter 6-week ( Study 301 ) 4-week ( Study 302 ) transition phase dose retigabine titrate maintain 400 mg TID ( Study 301 ) 300 mg TID ( Study 302 ) . Upon completion Transition phase , subject enrol extension study . Once enrolled OLE , dos could adjust within range 600 mg 1200 mg per day . Treatment Studies 303 304 plan continue regulatory approval commercialization retigabine program discontinue .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Ezogabine</mesh_term>
	<criteria>This metaanalysis therefore Inclusion/Exclusion criterion applicable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>retention rate</keyword>
	<keyword>epilepsy</keyword>
	<keyword>responder rate</keyword>
	<keyword>seizure freedom</keyword>
	<keyword>discontinuation rate</keyword>
	<keyword>safety assessment</keyword>
	<keyword>reduction seizure frequency</keyword>
	<keyword>open-label</keyword>
</DOC>